MX365321B - Métodos para el tratamiento de neutropenia mediante agonistas retinoides. - Google Patents
Métodos para el tratamiento de neutropenia mediante agonistas retinoides.Info
- Publication number
- MX365321B MX365321B MX2014014930A MX2014014930A MX365321B MX 365321 B MX365321 B MX 365321B MX 2014014930 A MX2014014930 A MX 2014014930A MX 2014014930 A MX2014014930 A MX 2014014930A MX 365321 B MX365321 B MX 365321B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating neutropenia
- neutropenia
- retinoid agonists
- subject
- Prior art date
Links
- 208000004235 neutropenia Diseases 0.000 title abstract 4
- 239000000556 agonist Substances 0.000 title abstract 2
- 150000004492 retinoid derivatives Chemical class 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención provee métodos para el tratamiento de la neutropenia en un sujeto que lo necesita que comprende la administración de una composición que comprende un agonista de retinoide y la administracion de una cantidad eficaz de la composición al sujeto para tratar la neutropenia, para así tratar la neutropenia en el sujeto que lo necesita.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261656815P | 2012-06-07 | 2012-06-07 | |
PCT/US2013/044828 WO2013185105A1 (en) | 2012-06-07 | 2013-06-07 | Methods for treating neutropenia using retinoid agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014014930A MX2014014930A (es) | 2015-07-06 |
MX365321B true MX365321B (es) | 2019-05-29 |
Family
ID=49712715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014930A MX365321B (es) | 2012-06-07 | 2013-06-07 | Métodos para el tratamiento de neutropenia mediante agonistas retinoides. |
Country Status (14)
Country | Link |
---|---|
US (1) | US11116738B2 (es) |
EP (1) | EP2858636B1 (es) |
JP (1) | JP6295249B2 (es) |
KR (1) | KR102083046B1 (es) |
CN (1) | CN104519879B (es) |
AU (1) | AU2013270674B2 (es) |
BR (1) | BR112014030279A2 (es) |
CA (1) | CA2874850A1 (es) |
ES (1) | ES2691493T3 (es) |
HK (1) | HK1208630A1 (es) |
MX (1) | MX365321B (es) |
NZ (1) | NZ702415A (es) |
RU (1) | RU2650962C2 (es) |
WO (1) | WO2013185105A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ702415A (en) | 2012-06-07 | 2016-04-29 | Children’S Hospital Los Angeles | Methods for treating neutropenia using retinoid agonists |
EP2969031A4 (en) | 2013-03-15 | 2017-03-08 | Avisenna Cosmetics LLC | Topical compositions for reducing aging effects |
RU2016136833A (ru) | 2014-02-18 | 2018-03-22 | Чилдрен'З Хоспитал Лос Анджелес | Композиции и способы для лечения нейтропении |
EP3967305A1 (en) | 2015-03-31 | 2022-03-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists |
US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
WO2018067946A1 (en) * | 2016-10-06 | 2018-04-12 | Syros Pharmaceuticals, Inc. | Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody |
WO2019147187A1 (en) * | 2018-01-26 | 2019-08-01 | Agency For Science, Technology And Research | Neutrophil subtypes |
CN113969261B (zh) * | 2020-07-06 | 2024-04-09 | 苏州市立医院(北区) | 三步法快速测定中性粒细胞趋化的方法 |
US20220378727A1 (en) * | 2021-05-14 | 2022-12-01 | The University Of Hong Kong | Dry powder formulations of tamibarotene for pulmonary and intranasal delivery |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5691196A (en) | 1992-12-31 | 1997-11-25 | American Cyanamid Company | Recombinant nucleic acid containing a response element |
US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
AU5611398A (en) | 1996-12-19 | 1998-07-15 | American Cyanamid Company | Method of treating or inhibiting neutropenia |
MXPA03002046A (es) | 2000-09-08 | 2003-07-24 | Massachusetts Inst Technology | Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion. |
US7119061B2 (en) | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
TW200505408A (en) | 2003-05-16 | 2005-02-16 | Kyowa Hakko Kogyo Kk | Agent for preventing and/or treating tissue disruption-accompanied diseases |
EP1621191A1 (en) | 2004-07-29 | 2006-02-01 | Werner Bollag | Treatment of inflammatory diseases by RXR Antagonists |
CN101094684A (zh) | 2004-08-13 | 2007-12-26 | 阿诺麦德股份有限公司 | 用趋化因子的组合活化祖细胞/干细胞 |
AU2005310888B2 (en) | 2004-12-02 | 2011-01-06 | Venus Remedies Limited | Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection |
US20090111786A1 (en) | 2004-12-03 | 2009-04-30 | Glass Christopher K | Compounds that Prevent Macrophage Apoptosis and Uses Thereof |
JP2009537540A (ja) * | 2006-05-16 | 2009-10-29 | ビテ ファーマシューティカルズ, インコーポレイテッド | 化学療法および/または放射線療法の副作用を処置するためのrarアンタゴニストまたはrarインバースアゴニストの使用 |
US8252837B2 (en) | 2007-03-30 | 2012-08-28 | Tmrc Co., Ltd. | Tamibarotene capsule preparation |
EA201070687A1 (ru) * | 2007-12-06 | 2010-12-30 | Си Эс Эл ЛИМИТЕД | Способ ингибирования лейкозных стволовых клеток |
US8580516B2 (en) | 2008-09-05 | 2013-11-12 | University Of Chicago | Methods and compositions for direct detection of DNA damage |
JP2013508352A (ja) | 2009-10-19 | 2013-03-07 | ライラ ニュートラシューティカルズ | アセトゲニンを含む抽出物、フラクションおよび組成物ならびにそれらの応用 |
RU2446173C1 (ru) | 2010-08-13 | 2012-03-27 | Зао "Биокад" | Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе |
CN102380090A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | G-csf二聚体在治疗嗜中性粒细胞减少症中的应用 |
US9574179B2 (en) | 2011-02-08 | 2017-02-21 | Cellular Dynamics International, Inc. | Hematopoietic precursor cell production by programming |
JP6242868B2 (ja) * | 2012-05-08 | 2017-12-06 | リセラ・コーポレイションLycera Corporation | RORγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ[1,8]ナフチリジンスルホンアミドおよび関連化合物 |
NZ702415A (en) | 2012-06-07 | 2016-04-29 | Children’S Hospital Los Angeles | Methods for treating neutropenia using retinoid agonists |
DE102012011766B3 (de) | 2012-06-15 | 2013-12-19 | Voith Patent Gmbh | Getriebeeinheit |
CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
RU2016136833A (ru) | 2014-02-18 | 2018-03-22 | Чилдрен'З Хоспитал Лос Анджелес | Композиции и способы для лечения нейтропении |
-
2013
- 2013-06-07 NZ NZ702415A patent/NZ702415A/en not_active IP Right Cessation
- 2013-06-07 JP JP2015516261A patent/JP6295249B2/ja active Active
- 2013-06-07 RU RU2014153988A patent/RU2650962C2/ru not_active IP Right Cessation
- 2013-06-07 ES ES13800873.5T patent/ES2691493T3/es active Active
- 2013-06-07 EP EP13800873.5A patent/EP2858636B1/en not_active Not-in-force
- 2013-06-07 CN CN201380041537.6A patent/CN104519879B/zh active Active
- 2013-06-07 KR KR1020157000014A patent/KR102083046B1/ko active IP Right Grant
- 2013-06-07 AU AU2013270674A patent/AU2013270674B2/en not_active Ceased
- 2013-06-07 US US14/405,141 patent/US11116738B2/en active Active
- 2013-06-07 WO PCT/US2013/044828 patent/WO2013185105A1/en active Application Filing
- 2013-06-07 MX MX2014014930A patent/MX365321B/es active IP Right Grant
- 2013-06-07 BR BR112014030279A patent/BR112014030279A2/pt not_active Application Discontinuation
- 2013-06-07 CA CA2874850A patent/CA2874850A1/en not_active Abandoned
-
2015
- 2015-09-24 HK HK15109432.0A patent/HK1208630A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN104519879A (zh) | 2015-04-15 |
AU2013270674A1 (en) | 2014-12-18 |
JP6295249B2 (ja) | 2018-03-14 |
US11116738B2 (en) | 2021-09-14 |
WO2013185105A1 (en) | 2013-12-12 |
KR20150035983A (ko) | 2015-04-07 |
RU2650962C2 (ru) | 2018-04-18 |
NZ702415A (en) | 2016-04-29 |
EP2858636A1 (en) | 2015-04-15 |
RU2014153988A (ru) | 2016-07-27 |
US20150164836A1 (en) | 2015-06-18 |
CA2874850A1 (en) | 2013-12-12 |
JP2015523346A (ja) | 2015-08-13 |
AU2013270674B2 (en) | 2017-12-07 |
MX2014014930A (es) | 2015-07-06 |
EP2858636B1 (en) | 2018-09-05 |
CN104519879B (zh) | 2018-10-02 |
BR112014030279A2 (pt) | 2017-09-12 |
EP2858636A4 (en) | 2016-06-01 |
KR102083046B1 (ko) | 2020-02-28 |
ES2691493T3 (es) | 2018-11-27 |
HK1208630A1 (en) | 2016-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ702415A (en) | Methods for treating neutropenia using retinoid agonists | |
ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
MX2016002077A (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
MX2015009106A (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
MX2016007965A (es) | Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1. | |
MX369691B (es) | Inhibidores de glutaminasa y métodos de empleo. | |
MX2016012779A (es) | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. | |
MX2016004741A (es) | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. | |
MX2014007169A (es) | Tratamiento de trastorno autoinmune al usar agonistas de rxr. | |
MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
MX2018005544A (es) | Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer. | |
MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
MX348933B (es) | Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico. | |
MX2015009818A (es) | Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple. | |
NZ704496A (en) | Retinoids and use thereof | |
MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
WO2014146111A3 (en) | Analgesic compounds and methods of use | |
MY175326A (en) | Product and method for treating diarrhea | |
MX2016001104A (es) | Composiciones para tratar engrosamiento de la piel. | |
MX2013013182A (es) | Tratamiento de la mastitis. | |
MX2016005567A (es) | Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamin a (nmda). | |
MX2016002308A (es) | Tratamiento del mieloma multiple. | |
MX2016002307A (es) | Tratamiento para el cancer. | |
MX2012010006A (es) | Agonistas de a3ar para el tratamiento de uveitis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |